The Pore Region of the Skeletal Muscle Ryanodine Receptor Is a Primary Locus for Excitation-Contraction Uncoupling in Central Core Disease

GUILLERMO AVILA,1 KRISTEN M. S. O’CONNELL,2 AND ROBERT T. DIRKSEN3

1Department of Biochemistry, CINVESTAV – I. P. N., 2508 San Pedro, Zacatenco 07360, Mexico City, Mexico
2Department of Biomedical Sciences, Colorado State University, Ft. Collins, CO 80523
3Department of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642

ABSTRACT Human central core disease (CCD) is caused by mutations/deletions in the gene that encodes the skeletal muscle ryanodine receptor (RyR1). Previous studies have shown that CCD mutations in the NH2-terminal region of RyR1 lead to the formation of leaky SR Ca2+ release channels when expressed in myotubes derived from RyR1-knockout (dyspedic) mice, whereas a COOH-terminal mutant (I4897T) results in channels that are not leaky to Ca2+ but lack depolarization-induced Ca2+ release (termed excitation-contraction [EC] uncoupling). We show here that store depletion resulting from NH2-terminal (Y523S) and COOH-terminal (Y4795C) leaky CCD mutant release channels is eliminated after incorporation of the I4897T mutation into the channel (Y523S/I4897T and Y4795C/I4897T). In spite of normal SR Ca2+ content, myotubes expressing the double mutants lacked voltage-gated Ca2+ release and thus exhibited an EC uncoupling phenotype similar to that of I4897T-expressing myotubes. We also show that dyspedic myotubes expressing each of seven recently identified CCD mutations located in exon 102 of the RyR1 gene (G4890R, R4892W, I4897T, G4898E, G4898R, A4905V, R4913G) behave as EC-uncoupled release channels. Interestingly, voltage-gated Ca2+ release was nearly abolished (reduced ~90%) while caffeine-induced Ca2+ release was only marginally reduced in R4892W-expressing myotubes, indicating that this mutation preferentially disrupts voltage-sensor activation of release. These data demonstrate that CCD mutations in exon 102 disrupt release channel permeation to Ca2+ during EC coupling and that this region represents a primary molecular locus for EC uncoupling in CCD.

KEY WORDS: excitation-contraction coupling • skeletal muscle • calcium channel • muscle disease

INTRODUCTION

Excitation-contraction (EC)* coupling in skeletal muscle involves a mechanical interaction between dihydropyridine receptors (DHPR) in the sarcolemma and ryanodine receptors (RyR1) or Ca2+ release channels located in the terminal cisternae of the SR (Melzer et al., 1995). DHPR-RyR1 mechanical coupling is a bidirectional signaling interaction since DHPRs trigger the opening of SR Ca2+ release channels (orthograde coupling) and the presence of RyR1 enhances the Ca2+-conducting activity and modifies the L-channel gating properties of the DHPR (retrograde coupling) (Nakai et al., 1996; Avila and Dirksen, 2000; Dirksen, 2002). The central roles of DHPR and RyR1 proteins in normal skeletal muscle Ca2+ signaling is emphasized by the fact that mutations in both of these proteins account for several different human congenital muscle diseases (e.g., hypokalemic periodic paralysis, malignant hyperthermia [MH], and central core disease [CCD]) (Lehmann-Horn and Jurkat-Rott, 1999).

CCD is a human autosomal dominant, nonprogressive myopathy characterized by hypotonia and proximal muscle weakness in infancy (Shuaib et al., 1987). At least 32 different point mutations or deletions in the gene that encodes RyR1 are known to cause CCD in humans (for review see Dirksen and Avila, 2002). All of the CCD mutations identified to date are located within three relatively restricted regions of the RyR1 protein: 3 mutations in MH/CCD region 1 (residues 35–614), 4 mutations in MH/CCD region 2 (residues 2129–2458), and 15 mutations in MH/CCD region 3 (COOH-terminal region, including residues 4136–4973).

Functional studies of MH and CCD mutant RyR1s proteins expressed in either heterologous systems (e.g., HEK-293 cells) or skeletal myotubes derived from RyR1-knockout (dyspedic) mice indicate that CCD mutations in MH/CCD regions 1 and 2 lead to the formation of SR Ca2+ release channels that exhibit varying degrees of Ca2+ leak that manifests as an elevation in resting cal-
cium and a depletion of SR Ca\(^{2+}\) stores (Treves et al., 1994; Tong et al., 1997, 1999; Lynch et al., 1999; Monnier et al., 2000; Avila and Dirksen, 2001). As a consequence of store depletion, voltage-gated Ca\(^{2+}\) release during EC coupling is markedly reduced (Avila and Dirksen, 2001), presumably resulting from a reduction in both the driving force for Ca\(^{2+}\) release from the SR and the regulation of release channel activity by luminal Ca\(^{2+}\) (Sitasesan and Williams, 1997).

In contrast to that found for CCD mutations in MH/CCD regions 1 and 2, resting Ca\(^{2+}\) levels and SR Ca\(^{2+}\) content are normal in dyspedic myotubes expressing a COOH-terminal mutation in RyR1 (I4897T) (Avila et al., 2001a). Nevertheless, I4897T-expressing dyspedic myotubes do not release SR Ca\(^{2+}\) after stimulation by either caffeine or voltage and coexpression of wild-type and I4897T mutant RyR1 proteins only partially restores caffeine and voltage-gated Ca\(^{2+}\) release. These results suggest that the I4897T mutation leads to a functional uncoupling of sarcolemmal depolarization from the efficient release of SR Ca\(^{2+}\) (Avila et al., 2001a). We have referred to this phenomenon by which voltage-gated SR calcium release is reduced in a manner independent of changes in SR Ca\(^{2+}\) content in I4897T-expressing dyspedic myotubes as “EC uncoupling.” However, our suggestion that muscle weakness arising from the I4897T mutation operates via a fundamentally distinct mechanism (EC uncoupling) from that of the NH\(_2\)-terminal mutants (leaky channels) is controversial since other studies have suggested that I4897T mutant release channels act as leaky release channels in transfected HEK293 cells (Lynch et al., 1999) and lymphocytes obtained from CCD patients possessing this mutation (Tilgen et al., 2001).

We therefore set out to more rigorously test the validity of our hypothesis that the I4897T mutation operates via a fundamentally distinct cellular mechanism than that caused by CCD mutations that lead to enhanced SR Ca\(^{2+}\) leak. Our results indicate that normal levels of resting Ca\(^{2+}\) and SR Ca\(^{2+}\) content are restored after incorporation of the I4897T mutation into leaky channels. In addition, we found that all seven of the CCD mutations identified in exon 102 of the RyR1 gene lead to varying degrees of EC uncoupling following reconstitution in dyspedic myotubes, thus confirming this region of RyR1 as a primary molecular locus for EC uncoupling in CCD.

**MATERIALS AND METHODS**

**Preparation and cDNA Injections of Dyspedic Myotubes**

Primary cultures of myotubes were prepared from skeletal muscle of newborn dyspedic mice as described previously (Nakai et al., 1996; Avila and Dirksen, 2000). Each of the different CCD point mutations in RyR1 used in this study (Y523S, Y4795C, G4890R, R4892W, I4897T, G4898E, G4898R, A4990V, and R4913G) were introduced into a rabbit RyR1 cDNA using standard two-step site-directed mutagenesis strategies and the entire PCR-modified cDNA portion of each clone was ultimately confirmed by sequence analysis. Expression of wild-type RyR1 and the different CCD mutations in RyR1 was achieved by nuclear microinjection of cDNAs encoding CD8 (0.2 μg/μl) and the appropriate expression plasmid (0.5 μg/μl) 4–6 d after of initial plating of myoblasts (Avila et al., 2001a).

**Measurements of Resting Ca\(^{2+}\) and Caffeine-, 4-Chloro-m-Cresol-, and CPA-induced Ca\(^{2+}\) Transients in Intact Myotubes**

Resting Ca\(^{2+}\) and drug-induced changes in intracellular Ca\(^{2+}\) were measured in intact myotubes loaded with the fluorescent Ca\(^{2+}\) indicator Indo-1 AM (Molecular Probes) as described previously (Avila et al., 2001a,b). Indo-1–loaded myotubes were bathed in a normal rodent Ringer’s solution (containing 145 mM NaCl, 5 mM KC1, 2 mM CaCl\(_2\), 1 mM MgCl\(_2\), 10 mM HEPES, pH 7.4) and excited at 350 nm and 405 nm. Fluorescence emission at 405 nm was collected using a photomultiplier detection system and the results presented as the ratio of F\(_{405}\)/F\(_{485}\). The resting F\(_{405}/F_{485}\) ratio was converted to cytosolic Ca\(^{2+}\) levels using an in situ calibration approach described previously (Avila et al., 2001a). Relative changes in global Ca\(^{2+}\) levels were subsequently monitored after application of maximal concentrations of either caffeine (10 mM), 4-chloro-m-cresol (4-ccmc, 500 μM), or cyclopiazonic acid (CPA, 30 μM) using a rapid perfusion system that permits fast, local application of agonist as well as rapid washout with control solution (Avila et al., 2001a,b). In some experiments, Indo-1 AM–loaded myotubes bathed in Ringer’s were stimulated (8.0 V for 20 ms at 0.1 Hz for 30 s) using an extracellular pipette before the application of RyR1 agonists. Peak intracellular Ca\(^{2+}\) changes in response to agonist application are expressed as ΔR\(_{\text{agonist}}\) – R\(_{\text{baseline}}\).

**Simultaneous Measurements of Macroscopic Ca\(^{2+}\) Currents and Ca\(^{2+}\) Transients**

The whole-cell patch clamp technique was used to simultaneously measure L-currents and Ca\(^{2+}\) transients in expressing myotubes as described previously (Avila and Dirksen, 2000, 2001; Avila et al., 2001a,b). Four different series of experiments were carried out, and the results for each experimental condition are plotted with the corresponding control condition (RyR1). Thus, results obtained from RyR1-expressing myotubes were collected in four different groups: group I (n = 18), group II, (n = 14), group III (n = 8), and group IV (n = 9). Peak L-currents (linear components subtracted using a P/3 protocol) were normalized to cell capacitance (pA/pF), plotted as a function of the membrane potential, and fitted according to:

\[
\Delta F/F = \frac{(V_{m} - V_{1/2})}{V_{0.5}} \text{exp} \left[ \frac{(V_{m} - V_{1/2})}{k_{b}} \right]
\]

where \(V_{0.5}\) is the midpoint potential, and \(V_{1/2}\) is the extrapolated reversal potential of the Ca\(^{2+}\) current, \(V_{m}\) is the membrane potential during the test pulse, \(G_{\text{max}}\) is the maximum L-channel conductance, \(V_{1/2}\) is the voltage for half activation of \(G_{\text{max}}\), and \(k_{b}\) is a slope factor. Relative changes in cytosolic Ca\(^{2+}\) in patch clamp experiments were recorded in Fluo-3–dialyzed myotubes. Fluorescence traces were analogue filtered (τ = 0.5 ms, RC filter) before digitization at 10 kHz and expressed as \(\Delta F/F\) (F\(_{\text{peak}}\) – F\(_{\text{baseline}}\)). The magnitude of maximal voltage-gated calcium release (ΔF/F\(_{\text{max}}\)) was plotted as a function of the membrane potential, and fitted according to:

\[
\Delta F/F = \frac{(V_{m} - V_{1/2})}{1/1 + \text{exp} \left[ \frac{(V_{m} - V_{1/2})}{k_{b}} \right]}
\]

where \(\Delta F/F\) is the calculated maximal fluorescence change during the test pulse, \(V_{1/2}\) is the midpoint potential, and \(k_{b}\) is a slope factor. The internal solution contained (in mM): 145 Cs-aspartate, 10 CsCl, 0.1 CsA-EGTA, 1.2 MgCl\(_{2}\), 5 MgATP, 0.2 K\(_{2}\)-Fluo-3, 10 HEPES, pH 7.4. The external solution contained (in mM): 145 TEA-Cl, 10 CaCl\(_{2}\), 0.003 TTX, and 10 HEPES, pH 7.4.
All experiments were performed at room temperature (20–24°C) and data are presented as mean ± SEM. When indicated, significant differences (unpaired t tests) were determined using the software package Sigma Plot 2000 (SPSS). Statistic analysis was carried out by comparing every experimental condition versus its corresponding control group (RyR1) collected concurrently. Unless specified, differences were determined to be significant at P < 0.05.

RESULTS

The I4897T Mutation Blocks SR Ca\(^{2+}\) Leak through Y523S and Y4795C CCD Mutant Ca\(^{2+}\) Release Channels

We hypothesized that if the I4897T mutation results in SR Ca\(^{2+}\) release channels that poorly permeate Ca\(^{2+}\), then incorporation of this mutation into a leaky channel should restore normal levels of resting Ca\(^{2+}\) and SR Ca\(^{2+}\) content. To test this idea, we evaluated the effects of incorporating the I4897T mutation into a severely leaky NH\(_2\)-terminal CCD mutant release channel (Fig. 1, Y523S). For these experiments, myoplasmic Ca\(^{2+}\) levels were monitored in Indo-1 AM–loaded RyR1- and Y523S-expressing dyspedic myotubes before and after application of a maximal concentration of CPA, an agent that increases cytosolic Ca\(^{2+}\) by reversibly inhibiting SR Ca\(^{2+}\)-ATPase pumps. Compared with RyR1-expressing dyspedic myotubes, Y523S-expressing myotubes exhibit a substantially elevated resting Ca\(^{2+}\) level (Fig. 1 B) and a reduction in CPA-releasable SR Ca\(^{2+}\) stores (Fig. 1 C). Interestingly, increased SR Ca\(^{2+}\) leak can also result from a CCD mutations in the COOH-terminal region of RyR1 (MH and CCD region 3) since dyspedic myotubes expressing the Y4795C CCD mutation also exhibit elevated resting Ca\(^{2+}\) levels and a reduction in SR Ca\(^{2+}\) content (Fig. 1, Y4795C). Consistent with the hypothesis that the I4897T mutation disrupts Ca\(^{2+}\) permeation through SR Ca\(^{2+}\) release channels, expression of double mutant RyR1 proteins that incorporate both the I4897T and either Y523S (Y523S/I4897T) or Y4795C (Y4795C/I4897T) resulted in total restoration of normal levels of both resting Ca\(^{2+}\) and SR Ca\(^{2+}\) content (Fig. 1, B and C).

Voltage-gated SR Ca\(^{2+}\) Release Is Abolished in Y523S/I4897T- and Y4795C/I4897T-expressing Dyspedic Myotubes

Fig. 1 demonstrates that the I4897T mutation blocked Ca\(^{2+}\) leak through both Y523S and Y4795C CCD mutant release channels, consistent with a mutation that

---

**Figure 1.** The I4897T CCD mutation blocks SR Ca\(^{2+}\) leak through Y523S and Y4795C release channels. (A) Representative CPA-induced Ca\(^{2+}\) responses (30 μM CPA, gray bars) in Indo-1 AM–loaded dyspedic myotubes expressing wild-type RyR1, Y523S, Y4795C, I4897T, Y523S/I4897T, Y4795C/I4897T. A dotted line representing the average resting fluorescence of RyR1-expressing myotubes is shown for comparison. (B) Average resting Ca\(^{2+}\) levels of dyspedic myotubes expressing wild-type RyR1, Y523S, Y4795C, I4897T, Y523S/I4897T, Y4795C/I4897T, and Y4795C/I4897T. A dotted line representing the average resting fluorescence of RyR1-expressing myotubes is shown for comparison. (B) Average resting Ca\(^{2+}\) levels of dyspedic myotubes expressing wild-type RyR1, Y523S, Y4795C, I4897T, Y523S/I4897T, and Y4795C/I4897T. A dotted line representing the average resting fluorescence of RyR1-expressing myotubes is shown for comparison. (C) Average steady-state CPA-induced Ca\(^{2+}\) responses (Δ Ratio = R\(_{\text{CPA}}\) – R\(_{\text{baseline}}\)) for dyspedic myotubes expressing wild-type RyR1, Y523S, Y4795C, I4897T, Y523S/I4897T, Y4795C/I4897T. Asterisks indicate significant differences (P < 0.05) compared with RyR1.
disrupts Ca$^{2+}$ permeation of the release channel. We next used the whole-cell patch clamp technique in conjunction with a Ca$^{2+}$/H$^{+}$-sensitive dye to evaluate the impact of combining the I4897T mutation with NH$_2$-terminal and COOH-terminal leaky SR Ca$^{2+}$ channels on bidirectional coupling between DHPR and RyR1 proteins (Fig. 2). L-type Ca$^{2+}$ currents (I$\text{L}$-currents) and relative changes in intracellular Ca$^{2+}$ were simultaneously monitored during brief (30 ms) depolarizations to potentials between −50 and 70 mV. Similar to that observed for wild-type RyR1 and NH$_2$-terminal leaky CCD mutant release channels (Avila and Dirksen, 2001), expression of the Y4795C CCD mutant in dyspedic myotubes fully restored the Ca$^{2+}$-conducting activity of the DHPR (Fig. 2 B). However, maximal voltage-gated SR Ca$^{2+}$ release was significantly reduced (maximal ΔF/F was 38% smaller in Y4795C-expressing myotubes) and shifted ~15 mV to more hyperpolarizing potentials compared with that of RyR1 (Fig. 2, C and D). The large hyperpolarizing shift in the voltage dependence of SR Ca$^{2+}$ release is most clearly seen at threshold potentials (e.g., ~10 mV in Fig. 2 A). Thus, the effects of the Y4795C mutation were less severe than that of the Y523S mutation but quantitatively similar to that of the R164C CCD mutation (Avila and Dirksen, 2001).

Importantly, dyspedic myotubes expressing double mutants of I4897T and either Y523S (Y523S/I4897T) or Y4795C (Y4795C/I4897T) exhibited normal L-type Ca$^{2+}$ channel activity (Fig. 2 B), but lacked voltage-gated SR Ca$^{2+}$ release similar to that of I4897T-expressing myotubes (Fig. 2, A and C). The extremely small Ca$^{2+}$ transients observed in myotubes expressing the double mutants most likely arise from Ca$^{2+}$ influx through the DHPR since they were barely detectable (maximal ΔF/F ~0.1) and exhibited a bell-shaped voltage dependence identical to that of L-channel activation (Fig. 2, C and D), a result identical to that observed for I4897T-expressing myotubes (Avila et al., 2001a). Thus, the double mutants exhibit an EC uncoupling behavior identical to that of homozygous...
I4897T-expressing myotubes, demonstrating that the EC-uncoupling phenotype caused by the I4897T mutation dominates in myotubes expressing the double mutants.

**CCD Mutations in Exon 102 of the RyR1 Gene Result in EC Uncoupling**

Of the different CCD mutations in RyR1 that have been reconstituted in dyspedic myotubes, six are known to promote varying degrees SR Ca\(^{2+}\) leak (R164C, I404M, Y523S, R2163H, R2435H, Y4795C), whereas only one (I4897T) has been shown to function as an EC uncoupled channel (Avila and Dirksen, 2001; Avila et al., 2001a). However, if EC uncoupling represents an important cellular mechanism for muscle weakness in CCD, then other CCD mutations in RyR1 might also be expected to result in EC uncoupling. A logical place to start would be an analysis of the six newly identified CCD mutations (G4891R, R4893W, I4898T, G4899E, G4899R, A4906V, and R4914G) located in exon 102 of human RyR1 gene (Fig. 3 A), since this exon encodes the majority of the linker between RyR1 transmembrane regions 3 and 4 (in the model of Takeshima et al. [1989]) and the entire putative pore-lining/selectivity filter of the channel (Gao et al., 2000). Accordingly, we investig-
Molecular Locus of Excitation-Contraction Uncoupling

gated effects on resting Ca\(^{2+}\) and changes in intracellular Ca\(^{2+}\) after exposure to caffeine (10 mM) and CPA (30 μM) in dyspedic myotubes expressing each of the seven different exon 102 CCD mutations in RyR1 (Fig. 3 B). Resting Ca\(^{2+}\) levels (Fig. 3 C) and CPA responses (Fig. 3 D) were not significantly different between dyspedic myotubes expressing wild-type RyR1 and any of the exon 102 CCD mutations in RyR1, indicating that these mutations do not cause significant SR Ca\(^{2+}\) depletion. In spite of the presence of normal SR Ca\(^{2+}\) content, caffeine-induced SR Ca\(^{2+}\) release was reduced for each of the exon 102 CCD mutations in RyR1 (Fig. 3 E). Interestingly, caffeine-induced Ca\(^{2+}\) release was only partially reduced for two of the exon 102 mutant

release channels (see R4892W and A4905V in Fig. 3 E), indicating that SR Ca\(^{2+}\) release may only be partially reduced by these particular mutations. This effect was not due to a decrease in caffeine sensitivity since release was not greater for these constructs following the application of 30 mM caffeine (unpublished data).

We next characterized the effects of expression in dyspedic myotubes of the exon 102 CCD mutations on RyR1-mediated restoration of both voltage-gated SR Ca\(^{2+}\) release (orthograde coupling, defined as Ca\(^{2+}\) transients that exhibit a sigmoidal voltage-dependence) and L-type Ca\(^{2+}\) channel activity (retrograde coupling). Fig. 4 A shows representative Ca transients recorded from myotubes expressing wild-type RyR1.

![Figure 4](image-url)
The average peak L-current density (Fig. 4 B), Ca\(^{2+}\)-transient magnitude (Fig. 4 C), and the normalized voltage dependence of these Ca\(^{2+}\) transients (Fig. 4 D) for each exon 102 mutant is plotted (open circles) together with its matching control (RyR1, closed circles). Similar to that observed for I4897T (Avila et al., 2001a), homozygous expression of each of the other exon 102 CCD mutants fully restored L-type Ca\(^{2+}\) channel activity to a degree identical to that of wild-type RyR1 (Fig. 4 B). The complete restoration of retrograde coupling indicates that the exon 102 CCD mutants were synthesized, properly targeted to sarcolemmal-SR junctions, and functionally interacted with DHPRs present within these junctions.

In contrast to the complete restoration of retrograde coupling, voltage-gated SR Ca\(^{2+}\) release was absent in G4890R-, G4898E-, G4898R-, and R4913G-expressing dyspedic myotubes. Interestingly, maximal voltage-gated Ca\(^{2+}\) release was only partially reduced in dyspedic myotubes expressing R4892W (85%) and A4905V (36%), the same two constructs that also resulted in a partial reduction in caffeine-induced Ca\(^{2+}\) release (see Fig. 3). In spite of this reduction, voltage-gated Ca\(^{2+}\) release of R4892W- and A4905V-expressing myotubes exhibited a sigmoidal voltage dependence (Fig. 4, C and D, and representative traces in Fig. 4 A) that was not shifted significantly from that of wild-type RyR1 (\(V_{1/2}\) was 8.6 ± 1.1, 11.3 ± 1.8, and 8.9 ± 1.9 for RyR1-, R4892W-, and A4905V-expressing myotubes, respectively, \(P > 0.05\)).

**The R4892W Mutation Preferentially Disrupts Voltage Sensor Activation of the SR Ca\(^{2+}\) Release Channel**

Results obtained in Figs. 3 and 4 indicate that both caffeine and voltage-gated SR Ca\(^{2+}\) release are reduced to a similar degree for most of the exon 102 CCD mutations in RyR1. However, the R4892W mutation appeared somewhat unique in this regard since R4892W-expressing myotubes exhibited a large reduction in maximal voltage-gated SR Ca\(^{2+}\) release (~85%), whereas caffeine-induced Ca\(^{2+}\) release was only marginally reduced. To more rigorously test whether voltage-gated Ca\(^{2+}\) release is preferentially disrupted by the R4892W mutation in RyR1, we monitored electrically evoked and caffeine-induced Ca\(^{2+}\) release from individual Indo-1 AM–loaded myotubes expressing either RyR1, R4892W, or I4897T. For these experiments, voltage-gated Ca\(^{2+}\) release was first activated by a brief train of supramaximal electrical stimuli (8 V for 20 ms at 0.1 Hz for 30 s) using an extracellular electrode placed ad-
that were typically somewhat smaller than maximal Ca\(^{2+}\) release activated by 10 mM caffeine (Fig. 5 A, left). Similar to un.injected dyspedic myotubes, I4897T-expressing myotubes completely lacked Ca\(^{2+}\) transients in response to either electrical stimulation or exposure to the RyR1-selective agonist 4-cmc and responded only weakly or not at all to 10 mM caffeine (Fig. 5 A, right). The small caffeine response in un injected and I4897T-expressing dyspedic myotubes (see also Fig. 5 E) presumably arises from a low endogenous expression of the type 3 ryanodine receptor in dyspedic myotubes (Takeshima et al., 1995). On the other hand, although R4892W-expressing myotubes exhibited very small or undetectable electrically evoked Ca\(^{2+}\) transients, 10 mM caffeine (but not 4-cmc) was still able to induce a significant release of SR Ca\(^{2+}\) (Fig. 5 A, middle). Average responses of RyR1-, I4897T-, and R4892W-expressing myotubes to electrical stimulation, caffeine, and 4-cmc are summarized in Fig. 5 B. There was a strong correlation (r = 0.98) between the magnitude of maximal caffeine-induced and voltage-gated SR Ca\(^{2+}\) release (as determined in Fig. 4) for all of the exon 102 CCD mutations in RyR1 except R4892W (Fig. 5 C). Even the partial reduction in voltage- and caffeine-induced Ca\(^{2+}\) release observed in A4905V-expressing myotubes was adequately described by this correlation. Although we have not directly determined if R4892W-expressing myotubes are indeed capable of firing action potentials in response to an extracellular stimulus, the data presented in Figs. 3–5 provide compelling evidence that the R4892W mutation disrupts voltage sensor activation of release to a greater extent than that triggered by caffeine, making it unique among the identified CCD mutations in exon 102 of RyR1.

**DISCUSSION**

**Leaky Channels Can Result from CCD Mutations in the COOH-terminal Region of RyR1**

Based on results obtained after reconstitution of CCD mutant RyR1 proteins in dyspedic myotubes, we have proposed two fundamentally distinct cellular mechanisms for muscle weakness in CCD (leaky and EC uncoupled SR Ca\(^{2+}\) release channels) (Avila and Dirksen, 2001; Avila et al., 2001a; Dirksen and Avila, 2002). Our previous work has shown that expression of NH\(_2\)-terminal CCD mutants in dyspedic myotubes resulted in varying degrees of SR Ca\(^{2+}\) leak (reduced voltage-gated release resulting from SR Ca\(^{2+}\) depletion), while a COOH-terminal mutant (I4897T) results in EC uncoupling (reduced voltage-gated release in the absence of detectable store depletion). These observations raised the possibility that NH\(_2\)-terminal CCD mutations (MH/CCD regions 1 and 2) result in leaky release channels while COOH-terminal CCD mutations result in EC uncoupling (MH/CCD region 3). However, such a clear structural division between mechanisms does not appear to be accurate since we now show that a COOH-terminal CCD mutation (Y4795C) also exhibits all the hallmarks of an NH\(_2\)-terminal leaky SR Ca\(^{2+}\) release channel (elevated resting Ca\(^{2+}\), reduced SR Ca\(^{2+}\) content, hyperpolarized-shifted \(V_{1/2}\), reduced maximal \(\Delta F/F\)).

**CCD Mutations in the Pore Region of RyR1 Markedly Reduce SR Ca\(^{2+}\) Release**

Our proposal that the I4897T mutation operates via a mechanism distinct from that of leaky CCD mutant release channels is controversial since I4897T mutant release channels promote Ca\(^{2+}\) leak from intracellular Ca\(^{2+}\) stores after expression in HEK293 cells (Lynch et al., 1999). In addition, increased SR Ca\(^{2+}\) leak was also observed in human lymphocytes obtained from CCD patients heterozygous for the I4897T mutation (Tilgen et al., 2001). To more rigorously test our hypothesis that the I4897T mutation leads to SR Ca\(^{2+}\) release channels that poorly permeate Ca\(^{2+}\) in a skeletal muscle environment, we determined whether the I4897T mutation could block SR Ca\(^{2+}\) depletion caused by leaky CCD mutant release channels. Accordingly, we found that incorporation of the I4897T mutation into leaky release channels arising from either NH\(_2\)-terminal (Y523S) or COOH-terminal (Y4795C) CCD mutations in RyR1 blocked the ability of these mutations to cause store depletion and an elevation in resting Ca\(^{2+}\).

In addition, although the I4897T mutation prevented SR Ca\(^{2+}\) leak through leaky CCD mutant release channels, myotubes expressing the double mutants were EC uncoupled since they completely lacked voltage-gated SR Ca\(^{2+}\) release (i.e., Ca\(^{2+}\) transients that exhibit a sigmoidal voltage dependence). These results support the idea that the I4897T mutation greatly inhibits Ca\(^{2+}\) permeation through the SR Ca\(^{2+}\) release channel.

As a second test, we surmised that if EC uncoupling represents an important cellular mechanism for muscle weakness in CCD, then other CCD mutations in RyR1 would also be likely to operate via this mechanism. Exon 102 of the gene encoding the human RyR1 protein encodes 52 amino acids, including the entire putative RyR pore-lining/selectivity filter of the channel. Exon 102 apparently represents a highly susceptible region for CCD since seven different disease causing mutations within six different amino acid residues have been identified to date. We hypothesized that muta-
tions to key pore-lining residues of the channel encoded by exon 102 that contribute significantly to Ca\(^{2+}\) permeation of the open channel would result in ECC-uncoupled release channels. Our results indicate that all of the exon 102 CCD mutations in RyR1 result in a marked reduction in voltage-gated SR Ca\(^{2+}\) release that occurs in the absence of a measurable change in resting Ca\(^{2+}\) or SR Ca\(^{2+}\) content, confirming that this region of RyR1 represents a primary molecular locus for ECC uncoupling in CCD.

Homozygous expression in dyspedic myotubes of five of the seven identified exon 102 CCD mutations in RyR1 (G4890R, I4897T, G4898E, G4898R, and R4913G) results in a complete loss of voltage-gated SR Ca\(^{2+}\) release that occurs in the absence of a significant change in either resting Ca\(^{2+}\), SR Ca\(^{2+}\) content, or retrograde coupling with sarcolemmal DHPRs (complete EC uncoupling). However, the other two exon 102 mutations were unique in that voltage-gated SR Ca\(^{2+}\) release was only partially reduced (~85% for R4892W and ~36% for A4905V; partial ECC uncoupling). Although reduced in magnitude, the residual voltage-gated Ca\(^{2+}\) release attributable to these mutants exhibited a voltage dependence (V\(_{1/2}\)) that was not significantly different from that of wild-type RyR1. The normal voltage dependence of Ca\(^{2+}\) release in R4892W- and A4905V-expressing myotubes is similar to what we have shown previously for the partial restoration of release observed after coexpression of wild-type RyR1 and I4897T (Avila et al., 2001a). Thus, the normal voltage dependence of partially uncoupled release channels provides strong evidence in support of the conclusion that the exon 102 mutations result in a fundamentally distinct phenotype from that which arises from mutations that lead to leaky SR Ca\(^{2+}\) release channels.

Caffeine and voltage-gated Ca\(^{2+}\) release were reduced to a similar degree for all but one of the exon 102 mutants (Fig. 5 C). These results could be explained by exon 102 mutations that inhibit Ca\(^{2+}\) flux through the release channel in a manner that is independent of the precise activation mechanism. This could occur by mutations that alter the gating and/or Ca\(^{2+}\) permeation of the open release channel. The one exception to this rule was that voltage-gated Ca\(^{2+}\) release through R4892W mutant release channels was reduced to a far greater extent than that observed upon addition of caffeine (Fig. 5). These results demonstrate that R4892W mutant release channels are in fact able to conduct Ca\(^{2+}\) ions under certain activation paradigms (e.g., caffeine) but not others (voltage, 4-cmc). In addition, since the R4892W mutation inhibited voltage-gated and 4-cmc-induced Ca\(^{2+}\) release similarly, it is tempting to speculate that 4-cmc may activate RyR1 by a mechanism analogous to that of the voltage sensor. In any event, these results indicate that while voltage-gated Ca\(^{2+}\) release is reduced for all EC-uncoupled release channels, ECC uncoupling is not necessarily synonymous with a Ca\(^{2+}\)-impermeant channel. Thus, in addition to altering the pore of the release channel, it is conceivable that ECC uncoupling (i.e., reduced voltage-gated release in the absence of store depletion) could also arise from CCD mutations in RyR1 (or the DHPR) that either (a) perturb RyR1 (or DHPR) junctional targeting, (b) result in DHPR/RyR1 expression level mismatch, (c) alter appropriate assembly of DHPR tetrad or RyR1 arrays, or (d) disrupt functional coupling between properly targeted/assembled DHPR and RyR1 proteins (Dirksen and Avila, 2002). Thus, while mutations within exon 102 of the RyR1 gene represent a hotspot for ECC uncoupling, mutations within other functional domains of the channel could potentially lead to mechanistically distinct forms of ECC uncoupling.

**Therapeutic Implications for Two Distinct Mechanisms of Muscle Weakness in CCD**

Currently, there are no effective therapies for the treatment of muscle weakness or core development in CCD. However, normalization of muscle Ca\(^{2+}\) homeostasis by interventions expected to block SR Ca\(^{2+}\) leak could potentially improve muscle performance in forms of CCD that result from excessive leak of SR Ca\(^{2+}\) through CCD mutant RyR1 channels. Our results in which resting Ca\(^{2+}\) and SR Ca\(^{2+}\) content are restored to normal levels in dyspedic myotubes expressing double mutants that combine the I4897T “EC uncoupled” mutation with NH\(_{2}\)-terminal or COOH-terminal “leaky” channels (Fig. 1) provides sound preliminary rationale for such an idea. However, although levels of resting Ca\(^{2+}\) and SR Ca\(^{2+}\) content are normal, EC coupling is completely “uncoupled” (i.e., no voltage-gated release) in myotubes expressing the double mutants; a result not unexpected if the I4897T mutation results in release channels that only poorly permeate Ca\(^{2+}\). Thus, any effective therapeutic approach designed to counteract SR Ca\(^{2+}\) loss through leaky SR Ca\(^{2+}\) release channels would need to restore both resting Ca\(^{2+}\) and SR content and also promote normalization of voltage-gated SR Ca\(^{2+}\) release.

Dantrolene, an FDA-approved agent used in the treatment of MH crises (McCarthy et al., 2000), may represent an intriguing candidate for counteracting Ca\(^{2+}\) dysregulation resulting from leaky SR Ca\(^{2+}\) release channels. Dantrolene is thought to antagonize MH episodes by reducing skeletal muscle twitch force and shifting the sensitivity of contractile activation to more depolarized voltages (Hainaut and Desmedt, 1974), an effect diametrically opposed to that caused by CCD mutations in RyR1 that result in leaky SR Ca\(^{2+}\) release channels (where the voltage dependence of Ca\(^{2+}\) release is shifted to more hyperpolarized potentials) (Fig.
2; Avila and Dirksen, 2001). However, the precise mechanism by which dantrolene alters SR Ca$^{2+}$ release is still unclear since a more recent report has shown that dantrolene reduces the amplitude of voltage-gated SR Ca$^{2+}$ release without altering the voltage dependence of Ca$^{2+}$ release in rodent skeletal muscle fibers (Szentesi et al., 2001). Nevertheless, it will be important for future experiments to determine whether dantrolene can normalize resting Ca$^{2+}$, SR Ca$^{2+}$ content, as well as the magnitude and voltage dependence of Ca$^{2+}$ release attributable to leaky CCD mutant release channels. In such a case, dantrolene could potentially oppose muscle weakness that arises from leaky release channels (e.g., by inhibiting SR Ca$^{2+}$ loss through leaky channels) while exacerbating muscle weakness resulting from mutations that lead to EC uncoupling (e.g., by further inhibiting Ca$^{2+}$ release through EC uncoupled release channels). Such observations would emphasize the importance of combining information gleaned from genetic screening of kindreds with the development and application of specific therapeutic approaches for improving muscle strength in CCD.

We would like to thank Drs. Kurt G. Beam and Paul D. Allen for providing us access to the dyspedic mice used in this study and to Linda Groom for excellent technical assistance. This work was supported by the National Institutes of Health (AR4657 to R.T. Dirksen) and a Neuromuscular Disease Research grant from the Muscular Dystrophy Association (to R.T. Dirksen).

Olaf S. Andersen served as editor.

Submitted: 8 January 2003
Revised: 19 February 2003
Accepted: 19 February 2003

REFERENCES

Avila, G., and R.T. Dirksen. 2000. Functional impact of the ryanodine receptor on the skeletal muscle L-type Ca$^{2+}$ channel. J. Gen. Physiol. 115:467-480.

Avila, G., and R.T. Dirksen. 2001. Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor. J. Gen. Physiol. 118:277-290.

Avila, G., J.J. O’Brien, and R.T. Dirksen. 2001a. Excitation-contraction uncoupling by a human central core disease mutation in the ryanodine receptor. Proc. Natl. Acad. Sci. USA. 98:4215-4220.

Avila, G., K.M. O’Connell, L.A. Groom, and R.T. Dirksen. 2001b. Ca$^{2+}$ release through ryanodine receptors regulates skeletal muscle L-type Ca$^{2+}$ channel expression. J. Biol. Chem. 276:17732-17738.

Dirksen, R.T. 2002. Bi-directional coupling between dihydropyridine receptors and ryanodine receptors. Front. Biosci. 7:d659-d670.

Dirksen, R.T., and G. Avila. 2002. Altered ryanodine receptor function in central core disease: leaky or uncoupled Ca$^{2+}$ release channels? Trends Cardiovasc. Med. 12:189-197.

Gao, L., D. Balshaw, L. Xu, A. Tripathy, C. Xin, and G. Meissner. 2000. Evidence for a role of the luminal M3-M4 loop in skeletal muscle Ca$^{2+}$ release channel (ryanodine receptor) activity and conductance. Biophys. J. 79:828-840.

Hainaut, K., and J.E. Desmedt. 1974. Effect of dantrolene sodium on calcium movements in single muscle fibres. Nature. 252:728-730.

Lehmann-Horn, F., and K. Jurkat-Rott. 1999. Voltage-gated ion channels and hereditary disease. Physiol. Rev. 79:1317-1372.

Lynch, P.J., J. Tong, M. Lehane, A. Mallet, L. Giblin, J.J. Heffron, P. Vaughan, G. Zafra, D.H. MacLennan, and T.V. McCarthy. 1999. A mutation in the transmembrane/luminal domain of the ryanodine receptor is associated with abnormal Ca$^{2+}$ release channel function and severe central core disease. Proc. Natl. Acad. Sci. USA. 96:4164-4169.

McCarthy, T.V., K.A. Quane, and P.J. Lynch. 2000. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum. Mutat. 5:410-417.

Melzer, W., A. Herrmann-Frank, and H.C. Luttgau. 1995. The role of Ca$^{2+}$ ions in excitation-contraction coupling of skeletal muscle fibres. Biochim. Biophys. Acta. 1241:59-116.

Monnier, N., N.B. Romero, J. Lerale, Y. Nivoche, D. Qi, D.H. MacLennan, M. Fardeau, and J. Lunardi. 2000. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RyR1 gene encoding the skeletal muscle ryanodine receptor. Hum. Mol. Genet. 9:2599-2608.

Nakai, J., R.T. Dirksen, H.T. Nguyen, I.N. Pessah, K.G. Beam, and P.D. Allen. 1996. Enhanced dihydropyridine receptor channel activity in the presence of ryanodine receptor. Nature. 380:72-75.

Shuaib, A., R.T. Pauske, and K.W. Brownell. 1987. Central core disease. Clinical features in 13 patients. Medicine (Baltimore). 66:389-396.

Sitsapesan, R., and A.J. Williams. 1997. Regulation of current flow through ryanodine receptors by luminal Ca$^{2+}$. J. Membr. Biol. 159:179-185.

Szentesi, P., C. Collet, S. Sarkosi, C. Szegedi, I. Jona, V. Jacquemond, L. Kovacs, and L. Csernoch. 2001. Effects of dantrolene on steps of excitation-contraction coupling in mammalian skeletal muscle fibers. J. Gen. Physiol. 118:355-375.

Takeshima, H., S. Nishimura, T. Matsumoto, H. Ishida, K. Kangawa, N. Minamino, H. Matsuo, M. Ueda, M. Hanaoka, and T. Hirose. 1989. Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor. Nature. 339:430-445.

Takeshima, H., T. Yamazawa, T. Ikemoto, M. Nishi, T. Noda, and M. Iino. 1995. Ca$^{2+}$-induced Ca$^{2+}$ release in myocytes from dyspedic mice lacking the type-1 ryanodine receptor. EMBO J. 14:2999-3006.

Tilgen, N., F. Zorzato, B. Halliger-Keller, F. Muntoni, C. Sewry, L.M. Palmucci, C. Schneider, E. Hauser, F. Lehmann-Horn, C.R. Muller, and S. Treves. 2001. Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis. Hum. Mol. Genet. 10:2879-2887.

Tong, J., T.V. McCarthy, and D.H. MacLennan. 1999. Measurement of resting cytosolic Ca$^{2+}$ concentrations and Ca$^{2+}$ store size in HEK-293 cells transfected with malignant hyperthermia or central core disease mutant Ca$^{2+}$ release channels. J. Biol. Chem. 274:695-702.

Tong, J., H. Oyamada, N. Demaurex, S. Grinstein, T.V. McCarthy, and D.H. MacLennan. 1997. Caffeine and halothane sensitivity of intracellular Ca$^{2+}$ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J. Biol. Chem. 272:26392-26399.

Treves, S., F. Larini, P. Menegazzi, T.H. Steinberg, M. Koval, B. Vilsen, J.P. Andersen, and F. Zorzato. 1994. Alteration of intracellular Ca$^{2+}$ transients in COS-7 cells transfected with the cDNA encoding skeletal-muscle ryanodine receptor carrying a mutation associated with malignant hyperthermia. Biochem. J. 301:661-665.